Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Cunningham

Showing results (571-580 of 622) with videos related to

Pageof 63
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2019
Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric CancerFilippo Pietrantonio, Rosalba Miceli, Alessandra Raimondi, et al.
Cancers|November 27, 2021
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNAKaren Aughton, Nils O Elander, Anthony Evans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2025
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled AnalysisAlessandra Raimondi, Gabriele Tinè, Alexej Ballhausen, et al.
Microbiome|May 9, 2023
Pathobionts in the tumour microbiota predict survival following resection for colorectal cancerJames L Alexander, Joram M Posma, Alasdair Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 studyJuan W Valle, Daniel Palmer, Richard Jackson, et al.
JAMA|September 9, 2010
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trialJohn P Neoptolemos, Deborah D Stocken, Claudio Bassi, et al.
The Lancet. Oncology|March 30, 2019
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 studyJohn N Primrose, Richard P Fox, Daniel H Palmer, et al.
Clinical Chemistry|August 29, 2018
Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA SequencingSonia Mansukhani, Louise J Barber, Dimitrios Kleftogiannis, et al.
JCO Precision Oncology|October 5, 2020
Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 TrialElisa Fontana, Gift Nyamundanda, David Cunningham, et al.
Leukemia & Lymphoma|July 16, 2021
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignanciesGraham P Collins, Tracy N Clevenger, Kathleen A Burke, et al.
Pageof 63

Showing results (571-580 of 622) with videos related to

Sort By:
Pageof 63
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2019
Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric CancerFilippo Pietrantonio, Rosalba Miceli, Alessandra Raimondi, et al.
Cancers|November 27, 2021
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNAKaren Aughton, Nils O Elander, Anthony Evans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2025
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled AnalysisAlessandra Raimondi, Gabriele Tinè, Alexej Ballhausen, et al.
Microbiome|May 9, 2023
Pathobionts in the tumour microbiota predict survival following resection for colorectal cancerJames L Alexander, Joram M Posma, Alasdair Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 studyJuan W Valle, Daniel Palmer, Richard Jackson, et al.
JAMA|September 9, 2010
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trialJohn P Neoptolemos, Deborah D Stocken, Claudio Bassi, et al.
The Lancet. Oncology|March 30, 2019
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 studyJohn N Primrose, Richard P Fox, Daniel H Palmer, et al.
Clinical Chemistry|August 29, 2018
Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA SequencingSonia Mansukhani, Louise J Barber, Dimitrios Kleftogiannis, et al.
JCO Precision Oncology|October 5, 2020
Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 TrialElisa Fontana, Gift Nyamundanda, David Cunningham, et al.
Leukemia & Lymphoma|July 16, 2021
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignanciesGraham P Collins, Tracy N Clevenger, Kathleen A Burke, et al.
Pageof 63